Vertex nabs ViaCyte's rival diabetes stem cell treatment, acquiring the biotech for $320M in cash - Endpoints News

Less than a week after the FDA lifted a hold on Vertex’s stem cell therapy for type 1 diabetes, the Boston company is buying out a rival in an all-cash deal. Vertex announced Monday morning it would acquire private biotech ViaCyte for $320 million in cash, a …

A nine-figure raise is a lot of money for private biotechs, and something that many are eager to publicize. But one startup is keeping its mouth almost completely shut about a new funding round, inst… [+386 chars]

full article...